ECEoin J. Cotter

Eoin J. Cotter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eoin J. Cotter has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Building Brain Health: development of a brain health community framework

    by Eoin J Cotter, Reyhana Cushnan, Macarena Espina Diaz, Thomas Grey, Niamh Randall, Michael Byrne, Brian Lawlor

    Introduction: There is increasing evidence that brain health is determined through exposure to multiple factors across the life course. For this reason, adopting a brain health-informed approach to housing design, delivery and community development is important. However, the conceptual and practical tools and approaches that speak to these issues are underdeveloped. Objective(s): We developed a conceptual brain health community framework as an initial activity in a project to adopt brain health principles within an existing multigenerational social housing development. Methods: This framework, called the Brain Health Community Framework, was developed through expert consensus, drawing on relevant sectors and disciplines, with international input. The framework was also used to structure a needs assessment workshop with the community. Results: This values-based framework comprises six pillars, along with key principles, enablers and barriers to implementation allocated to each pillar. Discussion: While preliminary, the framework is presented as a conceptual ‘starting point’ for organisations and communities seeking to develop brain health approaches to housing and community development.

  • Open Access

    Public Patient Involvement for Global Impact: Integrating Principles and Training into an International Brain Health Program

    by Eoin J Cotter, Abhisweta Bhattacharjee, Ciara O' Reilly, Mary Warbelow, Michael Foley, Sarah Fox, Stacey Yamamoto, Miriam Galvin, Eve Curran, Helen Bundy Medsger, et al.

    Introduction: The Global Brain Health Institute (GBHI) aims to address global brain health challenges through equity-based fellowship training in brain health leadership across sciences, arts, humanities, advocacy, and policy. To achieve this, Patient and Public Involvement (PPI) is essential within GBHI’s training programs. Objectives: To describe the development and implementation of PPI practice into GBHI to support up-scaling of PPI beyond the program through training of Fellows. Methods: The PPI implementation project had three main components: (1) Establishing a PPI panel including individuals with dementia, care partners, and those at risk, to contribute to GBHI activities, integrating the activity into the existing GBHI structure using Kotter’s organizational change framework; (2) Developing and implementing a PPI education program for GBHI trainees; and (3) Creating a network of GBHI fellows worldwide, to implement PPI practice in their home countries. An evaluation framework captured outputs and impact, focusing on; implementation milestones, program-specific outputs, impact of PPI training on fellows’ knowledge, awareness, using the Kirkpatrick model of training evaluation. Results: A PPI panel was established with individuals from the US and Ireland, actively contributing to GBHI’s communications, advocacy, and research efforts. A PPI training program was successfully integrated into the GBHI curriculum. The training was well-received, with Fellows incorporating PPI into their project work. Additionally, a cohort of 16 GBHI Alumni (Fellows who had graduated from the GBHI fellowship programme) from various countries was formed to develop a global resource framework for PPI in dementia research. Conclusion: The project successfully integrated PPI as a core and sustainable element of GBHI’s structure, generating interest and action across its global community.

  • Education and training to develop leaders in dementia and brain health

    by Eoin Cotter, Brian Lawlor, Claudia Duran-Aniotz, Agustin Ibañez, Iracema Leroi, Sanjib Saha, Adetunji Wilson-Taylor

    The chapter examines education and training initiatives aimed at improving dementia care in majority-world settings. It highlights three key programs that promote equitable partnerships between high-income countries (HICs), upper-middle-income countries, and lower and middle-income countries (LMICs). The first initiative is the Atlantic Fellows for Equity in Brain Health fellowship at the Global Brain Health Institute (GBHI), which trains interdisciplinary leaders to address dementia prevention and brain health challenges globally. The second initiative, which includes various Latin America-based education and training initiatives, focuses on regional brain health issues, promoting research, education, and policy initiatives tailored to Latin America’s unique context. The Latin American initiatives (i.e., BrainLat, ReDLat) aim to integrate brain research into national health agendas while enhancing capacity among healthcare professionals and policymakers. Lastly, the International Dementia Academy South Asia (IDASA) provides dementia training to address the significant shortage of trained professionals in countries like India and Bangladesh. These initiatives collectively aim to build local capacities, foster collaboration among stakeholders, and create sustainable improvements in dementia care, ultimately contributing to a global community of practice that enhances brain health outcomes in the majority world. By addressing local needs through targeted education and training, these programs strive to mitigate the growing burden of dementia in resource-limited settings.

  • Systemic gene dysregulation in classical Galactosaemia: Is there a central mechanism?

    by K.P. Coss, E.P. Treacy, E.J. Cotter, I. Knerr, D.W. Murray, Y.S. Shin, P.P. Doran


  • Open Access

    Expression of neuroepithelial transforming gene 1 is enhanced in oesophageal cancer and mediates an invasive tumour cell phenotype

    by Conor Lahiff, Eoin Cotter, Rory Casey, Peter Doran, Graham Pidgeon, John Reynolds, Padraic MacMathuna, David Murray

    Neuroepithelial Transforming Gene 1 (NET1) is a well characterised oncoprotein and a proven marker of an aggressive phenotype in a number of cancers, including gastric adenocarcinoma. We aimed to investigate whether NET1 plays a functional role in oesophageal cancer (OAC) and its pre-malignant phenotype Barrett’s oesophagus. Baseline NET1 mRNA levels were determined by qPCR across a panel of six cell lines, including normal oesophageal, Barrett’s and OAC derived cells. Quantification of NET1 protein in OAC cells was performed using Western blot and immunofluorescence. NET1 expression was modulated by treating with lysophosphatidic acid (LPA) and NET1-specific siRNA. The functional effects of NET1 knockdown were assessed in vitro using proliferation, migration and invasion assays. NET1 expression was increased in Barrett’s and in OAC-derived cells in comparison to normal oesophageal cells. The highest expression was observed in OE33 a Barrett’s-related OAC cell line. NET1 protein and mRNA expression was enhanced by LPA treatment in OAC and furthermore LPA treatment caused increased proliferation, migration and invasion in a NET1-dependent manner. NET1 knockdown resulted in reduced OAC cell proliferation and invasion. As found in other malignancies, NET1 expression is elevated in OAC and its pre-malignant phenotype, Barrett’s oesophagus. NET1 promotes OAC cell invasion and proliferation and it mediates LPA-induced OAC cell migration.


  • HIV-Associated Osteoporosis in Ireland: Prevalence and Risk Factors

    by Nicholas S Chew, Gerard S Sheehan, John Lambert, Samuel J McConkey, Eoin J Cotter, Peter P Doran, William G Powderly

    Effective antiretroviral therapy has transformed HIV infection into a chronic disease. The emphasis is now on the management of the consequences of life-long treatment and associated toxicities, including osteoporosis and fragility fractures. There is a paucity of data on HIV-associated osteoporosis in Ireland. Aims: The study aims to investigate the prevalence and relevant risk factors for HIV-associated osteoporosis. Methods: A cross-sectional study of 146 HIV-positive patients from two different tertiary referral hospitals in Dublin was employed. Results: The prevalence of osteopenia and osteoporosis of the hip and/or lumbar spine was 53.4 and 9.6%, respectively. We found significant association between decreased hip bone mineral density (BMD) and increasing age, male gender, cigarette smoking, ethnicity, intravenous drug use and lower nadir CD4. A low BMI was the single most important independent predictor of reduced BMD in our study cohort. Conclusion: Low BMD affects a large proportion of HIV-positi...


  • HIV Type 1 Alters Mesenchymal Stem Cell Differentiation Potential and Cell Phenotype ex Vivo

    by Eoin J. Cotter, Nicholas Chew, William G. Powderly, Peter P. Doran

    An increased incidence of bone and lipid toxicities is associated with HIV-1 infection and its treatment. Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into both osteoblasts (OB) and adipocytes (AC). We hypothesize that the interaction of MSC and HIV-1 underlie these toxicities. Serum was collected from uninfected control and HIV-infected, antiviral-naive patients. Sera were divided into three groups: HIV-negative sera ( n = 5), HIV-positive low viral load (LVL) (VL range 120; 4000, n = 5) or high viral load (HVL) (VL range 100,000; 500,000, n = 5). MSCs were exposed to these sera (5%) in an adipogenic/osteogenic condition and in nondifferentiating conditions in acute and chronic exposure models. Markers of adipogenesis/osteogenesis were examined in both MSCs induced to differentiated and nondifferentiating cells. Sera from HVL HIV-1-infected individuals induced a clear proadipogenic phenotype, as evidenced by an increase in adipocyte formation and the induction of increased expression of adipogenic markers including LPL and PPARγ. Both CD4 receptor blockade and treatment with the antiretroviral AZT attenuated these proadipogenic effects, suggesting that an infection event may underlie the observed phenomena. Finally, inhibition of COUP TF-1 by HIV-1 TAT was identified as a potential molecular mechanism for these effects. These results suggest that HIV-1 directly interacts with and may infect MSCs resulting in alterations of their differentiation potential, findings that significantly enhance our understanding of HIV-1-associated bone and fat toxicities.


  • Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment

    by Eoin J. Cotter, Peter P. Doran, William G. Powderly

    HIV-1 exerts its most profound effects through destruction of the hosts immune responses specifically through targeting of the T-lymphocyte populations. In addition to its primary immune target, HIV-1 also targets cells of the nervous, skeletal and vascular system. There is emerging evidence to suggest that HIV-1 may, in part at least, affect these diverse tissues by impairing the homeostatic production of terminally differentiated cells from stem and progenitor cell populations. The interaction between HIV-1 and stem cell populations may serve to underpin the diverse nonimmunological effects of HIV-1. This review deals with the effect of HIV-1 infection on a number of progenitor cell types, with emphasis on delineating mechanisms of HIVs destructive effect on the body. Modification of these effects may represent novel avenues for exploration in our search for clinical interventions.